Ординатура / Офтальмология / Английские материалы / Ocular Oncology_Albert, Polans_2003

Although great care has been taken to provide accurate and current information, neither the author(s) nor the publisher, nor anyone else associated with this publication, shall be liable for any loss, damage, or liability directly or indirectly caused or alleged to be caused by this book. The material contained herein is not intended to provide specific advice or recommendations for any specific situation.

Trademark notice: Product or corporate names may be trademarks or registered trademarks and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress.

ISBN: 0-8247-4016-5

This book is printed on acid-free paper.

Headquarters

Marcel Dekker, Inc.

270 Madison Avenue, New York, NY 10016, U.S.A. tel: 212-696-9000; fax: 212-685-4540

Distribution and Customer Service

Marcel Dekker, Inc.

Cimarron Road, Monticello, New York 12701, U.S.A. tel: 800-228-1160; fax: 845-796-1772

Eastern Hemisphere Distribution

Marcel Dekker AG

Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-260-6300; fax: 41-61-260-6333

World Wide Web

http://www.dekker.com

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above.

Copyright # 2003 by Marcel Dekker, Inc. All Rights Reserved.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Current printing (last digit):

PRINTED IN THE UNITED STATES OF AMERICA

Preface

Ocular tumors are unique among the diseases of the eye, threatening both sight and life. Prior texts in oncology and ophthalmology have focused primarily on providing physicians with information about the treatment of eye tumors. Ocular Oncology differs in that it is our objective to present a comprehensive account of the most current basic and clinical science related to eye tumors, and to offer new ideas about innovative treatments derived from recent genetic, biochemical, and immunological studies. In addition, this book discusses the current status of clinical trials in ocular oncology, as well as provides an up-to-date review of risk and prognostic factors associated with eye tumors. Finally, current findings are presented from studies of animal models and their use to assess the efficacy of novel treatment modalities with potential for human treatment.

Ocular Oncology focuses on uveal melanoma and retinoblastoma, the principal tumors originating in the eyes of adults and children, respectively. Although considered uncommon diseases, we need to acknowledge that rare and uncommon diseases often provide insights into fundamental biological processes and advance the development of innovative treatments of more prevalent diseases. There is perhaps no better example in science than retinoblastoma, a rare childhood ocular tumor with an incidence of only 300 to 400 cases per year in the United States. Studies of retinoblastoma, however, funded by the National Eye Institute, led to the identification of the first tumor suppressor gene. Prior to these studies, cancer was considered solely a ‘‘gain of function’’ phenomenon; studies of retinoblastoma instigated a fundamental change in thinking and scientific approach. In addition, studies of retinoblastoma led to the identification of further genes and pathways involved in one of the most fundamental processes in biology, namely the molecular control of cellular growth. Likewise, while much attention has been focused recently on anti-angiogenic strategies for the treatment of solid tumors, new studies of uveal melanoma have revealed a form of non-endothelial-based tumor microcirculation, owing to the dedifferentiation of tumor cells, that may compromise anti-angiogenic treatments. The relevance of such an alternative circulatory pathway during the growth and progression of other types of cancer is now an active area of investigation, instigated by studies of a rare eye tumor.

v

Contents

1.Clinical Overview of Uveal Melanoma: Introduction to Tumors of

3.Epidemiology of Uveal Melanoma: Patient Characteristics, Risk

5.Genetics of Uveal Melanoma: Chromosomal Rearrangements and

6.Structural Alterations and Gene Expression in the Pathogenesis of

vii

Contributors

David H. Abramson, M.D., F.A.C.S. Department of Ophthalmology, New York Presbyterian Hospital, New York, New York, U.S.A.

Daniel M. Albert, M.D., M.S. Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, U.S.A.

Isabelle Audo, M.D., Ph.D. Laboratoire de Physiopathologie Cellulaire et Mole´culaire de la Re´tine, Hoˆpital Saint Antoine, Paris, France

James J. Augsburger, M.D. Department of Ophthalmology, University of Cincinnati College of Medicine; Department of Ophthalmology, The University Hospital; Division of Ophthalmology, Department of Surgery, Cincinnati Children’s Hospital Medical Center; and Division of Ophthalmology, Department of Surgery, Veteran’s Affairs Medical Center, Cincinnati, Ohio, U.S.A.

H. Culver Boldt, M.D. Department of Ophthalmology, University of Iowa, Iowa City, Iowa, U.S.A.

Jacobus J. Bosch, M.D. Department of Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts, U.S.A.

Vivette D. Brown, Ph.D. Division of Cancer Informatics, University Health Network, Toronto, Ontario, Canada

Helen S. L. Chan, M.D. Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada

Emily Y. Chew, M.D. Division of Epidemiology and Clinical Research, National Eye Institute/National Institutes of Health, Bethesda, Maryland, U.S.A.

Soesiawati R. Darjatmoko Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, U.S.A.

xi